Literature DB >> 21993873

Challenges of adherence and persistence with iron chelation therapy.

John B Porter1, Michael Evangeli, Amal El-Beshlawy.   

Abstract

Due to advances in medical sciences, many chronic diseases that formerly resulted in early death can now be effectively managed with long-term treatment regimens. Patients with potentially fatal anemias, for example, can be treated with ongoing blood transfusions and iron chelation therapy. Ensuring adherence and persistence is challenging, as the benefits of therapy are not perceived immediately. Poor adherence severely compromises the effectiveness of treatment and, therefore, improving compliance in terms of quality of life and health economics is critical. Although adherence to chelation therapy is generally poor, the availability of oral iron chelators may help to improve patient compliance. For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993873     DOI: 10.1007/s12185-011-0927-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  36 in total

1.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Arnold Ganser; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Gabor Domokos; Bernard Roubert; Christian Rose
Journal:  Leuk Res       Date:  2010-05-06       Impact factor: 3.156

Review 2.  The Medication Adherence Model: a guide for assessing medication taking.

Authors:  Mary Jayne Johnson
Journal:  Res Theory Nurs Pract       Date:  2002       Impact factor: 0.688

Review 3.  Deferoxamine pharmacokinetics.

Authors:  J B Porter
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

4.  Iron chelation adherence to deferoxamine and deferasirox in thalassemia.

Authors:  Felicia Trachtenberg; Elliott Vichinsky; Dru Haines; Zahra Pakbaz; Lauren Mednick; Amy Sobota; Janet Kwiatkowski; Alexis A Thompson; John Porter; Thomas Coates; Patricia J Giardina; Nancy Olivieri; Robert Yamashita; Ellis J Neufeld
Journal:  Am J Hematol       Date:  2011-05       Impact factor: 10.047

5.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors:  Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

Review 6.  Medication compliance and persistence: terminology and definitions.

Authors:  Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

7.  Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Authors:  Elliott Vichinsky; Zahra Pakbaz; Onyinye Onyekwere; John Porter; Paul Swerdlow; Thomas Coates; Peter Lane; Beatrice Files; Brigitta U Mueller; Lena Coïc; Gian Luca Forni; Roland Fischer; Peter Marks; Diana Rofail; Linda Abetz; Jean-Francois Baladi
Journal:  Acta Haematol       Date:  2008-04-11       Impact factor: 2.195

Review 8.  Medication compliance in the elderly.

Authors:  C Salzman
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

9.  Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.

Authors:  Diana Rofail; Linda Abetz; Muriel Viala; Claire Gait; Jean-Francois Baladi; Krista Payne
Journal:  Value Health       Date:  2008-07-11       Impact factor: 5.725

Review 10.  Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Ali Taher; Hagop M Kantarjian
Journal:  Oncologist       Date:  2009-04-13
View more
  20 in total

Review 1.  Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

Authors:  John Porter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload.

Authors:  Bérengère Koehl; Florence Missud; Laurent Holvoet; Ghislaine Ithier; Oliver Sakalian-Black; Zinedine Haouari; Emmanuelle Lesprit; André Baruchel; Malika Benkerrou
Journal:  J Vis Exp       Date:  2017-03-14       Impact factor: 1.355

4.  Implementation of an educational intervention to optimize self-management and transition readiness in young adults with sickle cell disease.

Authors:  Cecelia L Calhoun; Regina A Abel; Hai Ahn Pham; Shomari Thompson; Allison A King
Journal:  Pediatr Blood Cancer       Date:  2019-03-25       Impact factor: 3.167

5.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

6.  Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project.

Authors:  Sherif M Badawy; Amanda B Payne; Mary M Hulihan; Thomas D Coates; Suvankar Majumdar; Dominic Smith; Alexis A Thompson
Journal:  Br J Haematol       Date:  2021-08-24       Impact factor: 8.615

Review 7.  Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.

Authors:  Matt Shirley; Greg L Plosker
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

8.  Negative affect differentiation and adherence during treatment for thalassemia.

Authors:  Karin G Coifman; Gail S Ross; Dorothy Kleinert; Patricia Giardina
Journal:  Int J Behav Med       Date:  2014-02

9.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2017-12-14

10.  Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence.

Authors:  Chia Chee Chong; Adyani Md Redzuan; Jameela Sathar; Mohd Makmor-Bakry
Journal:  J Patient Exp       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.